Related Experiment Video
Updated: Aug 12, 2026

Detection of Foodborne Bacterial Pathogens from Individual Filth Flies
Published on: February 13, 2015
US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?
Roy Guharoy1, Edward P Krenzelok2
1Pharmacy, Baptist Health, Montgomery, AL and Infectious Diseases, University of Massachusetts Medical School, Worcester, MA, USA.
Abstract:
Recently, the US Food and Drug Administration (FDA) issued emergency use authorization (EUA) for convalescent plasma (CP) for the treatment of hospitalized patients with coronavirus disease 2019 based on a non-peer-reviewed, open-label, observational study. Issuance of an EUA without a proven randomized, controlled trial (RCT) sets a dangerous precedent since the premature action drives healthcare providers and patients away from RCTs that are essential for determining the efficacy and safety of CP. More caution should have been taken based on what was learned from the recent debacle related to the rescinded EUA of hydroxychloroquine and chloroquine, which were approved initially based on an anecdotal report. The FDA process for determining efficacy and safety must be based solely on data from RCTs in order to sustain public and professional trust for future treatment and vaccine efforts to be successful.
More Related Videos
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
08:24Loop-Mediated Isothermal Amplification for Screening Salmonella in Animal Food and Confirming Salmonella from Culture Isolation
Published on: May 20, 2020
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Regulation
Bioequivalence studies: Biowaivers
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions